SDR Ventures Advises The Weinberg Group on Acquisition by ProPharma Group
SDR served as the exclusive sell-side advisor to The Weinberg Group and identified ProPharma Group as a very good strategic fit. “As the pharmaceutical industry faces increasingly strict standards across heterogeneous regulatory environments in the global economy, they need comprehensive compliance solutions,” commented SDR’s Principal, Chris Bouck. “We were happy to achieve our core mission of helping owner-entrepreneurs realize the value they’ve created over decades of hard work and leverage our experience in the healthcare sector.” Matthew Weinberg noted, “I would recommend that business owners choose an investment banking partner that understands that selling their business is one of the most significant moments in their lives; SDR provided exactly that perspective for me.”
The Weinberg Group, based in Washington D.C., is a leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. For more than 35 years, The Weinberg Group has used scientific and regulatory acumen to provide FDA-focused regulatory and compliance services. ProPharma Group is a leading provider of compliance services now with more than 1,100 employees across the globe. With this acquisition, ProPharma Group’s service offering will expand to include highly specialized, U.S. based pre-approval/pre-clinical regulatory services, effectively establishing a true, end-to-end solution for its clients across the globe. “ProPharma Group was a natural fit for us,” said Matthew Weinberg, The Weinberg Group’s CEO. “Given both of our leading positions in the marketplace, adding our science-based regulatory and compliance skills to that of ProPharma Group’s provides all of our clients the ability to develop their products with both global and local outcomes in mind.”
The Weinberg Group aligns perfectly with ProPharma Group’s portfolio of high-value services for life science companies. “This acquisition further solidifies ProPharma Group’s position as a leading, globally integrated pharmaceutical services platform with world-class regulatory affairs and compliance services. We are confident the combination will accelerate ProPharma Group’s growth and enhance its reputation as a value-added partner to its clients” said Michael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners.
The full press release published by Linden Capital Partners can be found here.